Lysophosphatidic Acid in Oncogenesis
Lysophosphatidic Acid in Oncogenesis
批准号:
7735592
负责人:
XIANJUN FANG
金额:
$23.0万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-08-01 至 2011-06-30
关键词:
Age-MonthsAnimal ModelBiologicalBiological ProcessCell Differentiation processCell ProliferationCell physiologyCellsColon CarcinomaCytoskeletonDNA Sequence RearrangementDefectDevelopmentDistantEdg-7 ReceptorEmbryonic DevelopmentEndothelial CellsEnzymesFamilyFertilityG-Protein-Coupled ReceptorsGTP-Binding ProteinsGene TargetingGenesHumanIncidenceKnock-outKnockout MiceLeadLigandsLinkLiverLungLung AdenocarcinomaLymphomaLysophosphatidic Acid ReceptorsLysophospholipidsMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of ovaryMalignant neoplasm of thyroidMediatingMinorModelingMusMutant Strains MiceNeoplasm MetastasisNeoplastic Cell TransformationOncogenicPathway interactionsPhenotypePhospholipidsPilomatrixomaPlasmacytomaPlayPredispositionProductionPurinoceptorRegulationRenal carcinomaRoleSerumSignal PathwaySignal TransductionSphingosine-1-Phosphate ReceptorSubgroupTestingTumor SuppressionTumor Suppressor Proteinsabstractingcancer therapycell motilitychemical carcinogenchemical carcinogenesiseffusionin vivoinsightleiomyosarcomalysophosphatidic acidmalignant breast neoplasmmembermigrationnovelosteosarcomaoverexpressionreceptorreceptor couplingreceptor upregulationresponsesarcomasynergismtumortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Revised Abstract
Lysophosphatidic acid (LPA), a naturally occurring lysophospholipid, is a ligand of at least
five G protein-coupled receptors (LPA15). The LPA13 receptors are members of the endothelial
cell differentiation gene (Edg) family and couple to Gi, Gq, and G12/13 subunits of G proteins to
activate an array of intracellular signaling cascades, leading to cytoskeleton rearrangement, cell
proliferation, survival, and migration. Overexpression of the Edg LPA receptors and upregulation
of LPA production via LysoPLD/autotaxin (AIX) are common abnormalities found in various
human cancers. However, studies of oncogenic roles of LPA have been hampered by lack of in
vivo evidence or an animal model to show involvement of LPA signals in tumor development.
Recently, p2y9/GPR23/LPA4 of the purinergic receptor family and a related
GPR92/LPA5 are identified as novel LPA receptors. These two receptors are structurally
distant from the Edg LPA1..3 receptors and couple to Gq, GI 2/13 and Gs subunits. The
biological functions of LPA4 and LPA5 receptors, particularly their roles in cancer have not
been previously studied. We recently disrupted the Ipa4 gene by targeted deletion in mice.
Although the LPA4 is not required for embryonic development and fertility, we observed a
dramatic increase in development of spontaneous tumors in Ipa4 mutant mice. The tumors
include malignant lymphoma, lung adenocarcinoma, high-grade sarcoma, leiomyosarcoma,
plasmacytoma and pilomatrixoma. The wide spectrum of tumors found in these mice not only
provides direct evidence for aberrant LPA signaling in tumorigenesis but also raises the
possibility that LPA4 acts as a tumor suppressor. Our preliminary results further suggest that
lack of LPA4 sensitizes cells to LPA-induced cell motility and activation of specific intracellular
pathways. We therefore hypothesize that, in contrast to the Edg LPA receptors, LPA4
negatively regulates specific LPA signaling pathways and oncogenic activity of LPA. As
a result, the lack of LPA4 predisposes mice to tumor development. The hypothesis will be
tested through the following three Specific Aims:
Aim 1. To determine the role of LPA4 in tumor suppression in mice;
Aim 2. To elucidate the functions of LPA4 in LPA signal transduction;
Aim 3. To evaluate whether deletion of LPA4 increases susceptibility of mice to chemical
carcinogenesis
We will determine tumor incidence, histotypes and metastasis rate of tumors in two
independent lines of Ipa4 knockout mice in Aim 1. We will take advantage of the LPA4-deficient
cells and other knockdown or overexpression approaches to investigate the biological
functions of LPA4 in the regulation of LPA signal transduction and cellular responses (Aim 2).
In Aim 3, the tumor suppressive function of LPA4 will be further explored by examining the
susceptibility of LPA4 null mice to chemical carcinogens. These proposed studies together will
establish the role of LPA4 in tumor suppression and may lead to identification of novel anticancer
targets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
-
批准号:10599149
-
项目类别:
-
资助金额:$40.49万
-
财政年份:2019
-
负责人:XIANJUN FANG
-
依托单位:
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
-
批准号:10361537
-
项目类别:
-
资助金额:$40.63万
-
财政年份:2019
-
负责人:XIANJUN FANG
-
依托单位:
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
-
批准号:8333999
-
项目类别:
-
资助金额:$19.51万
-
财政年份:2011
-
负责人:XIANJUN FANG
-
依托单位:
Regulation of lipogenesis by lysophosphatidic acid in ovarian cancer
-
批准号:8177055
-
项目类别:
-
资助金额:$16.26万
-
财政年份:2011
-
负责人:XIANJUN FANG
-
依托单位:
Lysophosphatidic Acid in Oncogenesis
-
批准号:7876906
-
项目类别:
-
资助金额:$23.0万
-
财政年份:2004
-
负责人:XIANJUN FANG
-
依托单位:
Lysophospholipid in Neovascularization in Ovarian Cancer
-
批准号:7241458
-
项目类别:
-
资助金额:$21.92万
-
财政年份:2004
-
负责人:XIANJUN FANG
-
依托单位:
Lysophospholipid in Neovascularization in Ovarian Cancer
-
批准号:6774357
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2004
-
负责人:XIANJUN FANG
-
依托单位:
Lysophospholipid in Neovascularization in Ovarian Cancer
-
批准号:6919241
-
项目类别:
-
资助金额:$23.16万
-
财政年份:2004
-
负责人:XIANJUN FANG
-
依托单位:
Lysophospholipid in Neovascularization in Ovarian Cancer
-
批准号:7104837
-
项目类别:
-
资助金额:$22.59万
-
财政年份:2004
-
负责人:XIANJUN FANG
-
依托单位:
海外基金